

Dr. David L. Pompliano joins BioLeap's Advisory Board.

November 17, 2008

BioLeap LLC, a global leader in predictive drug discovery, is pleased to announce that David L. Pompliano, PhD has joined BioLeap's Advisory Board.

"Dr. Pompliano is broadly recognized in the pharmaceutical industry as a senior executive with extensive drug discovery and early development experience in infectious diseases, oncology and musculoskeletal diseases. We are privileged to have the opportunity to work with David as we leverage our new techniques in computational fragment-based ligand design to become the recognized leader in small molecule drug discovery and development", commented Dr. John Kulp, CEO of BioLeap. "I believe the BioLeap approach can truly accelerate the Drug Discovery process and is particularly useful when applied to historically intractable targets", commented Dr. David Pompliano, "I am pleased to be part of the team that is improving the process of drug design."

Dr. Pompliano has eighteen years of leadership experience in the pharmaceutical industry with a focus on driving strategic change in research and development. Most recently he served as Vice President, Worldwide Basic Head, Vaccines and Infectious Diseases Franchise for Merck Research Laboratories. Prior to Merck, David was Vice President, Head of Biology, Infectious Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline. Earlier in his career, David served as Executive Director and Head of Antimicrobial and Angiogenesis Research at DuPont Pharmaceuticals and as Director in the Department of Biochemistry at Merck Research Laboratories. As a drug hunter, David has contributed to the discovery or development of two marketed drugs (Tykerb and Altabax) and four drugs that have reached clinical proof of concept (pazopanib, ronacaleret, Rezonc, and Promacta). He is an internationally recognized scientist and innovator who has published >50 research papers, has given >25 invited lectures internationally and holds three patents for novel methods in drug discovery.

Dr. Pompliano received his B.S. (Chemistry) at the University of Virginia and his Ph.D. (Chemistry) from Stanford University. David was a NIH Post-Doctoral Fellow at Harvard University in the Department of Chemistry.

About BioLeap:

BioLeap intends to become the leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable leads for important biological targets. BioLeap has identified initial leads in four collaborative ventures and offers compelling lead identification and optimization services for new partners.

Contact:

Gerry Evans, EVP
BioLeap
215-371-2874
ghe@bioleap.com